Moleculin Biotech Inc

During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule10b5-1 trading arrangement or a non-Rule10b5-1 trading arrangement (each as defined in Item408 of Regulation S-K under the Securities Exchange Act of1934, as amended).

During the quarter ended* March 31, 2025,we terminated certain licenses related toWP1122* with MD Anderson and are in discussions to execute an option or options on these technologies along with additional technologies where the term of such options will be tied to the term of our Sponsored Research Agreement with MD Anderson. Such actions are in line with our efforts to focus our resources on the development of Annamycin. The terminated license agreements consist of: (i) the Patent and Technology License Agreement dated* April 2, 2012by and between The Board of Regents of the University of Texas System and IntertechBio Corporation, as amended; (ii) the Patent And Technology License Agreement dated December 3, 2021by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M. D. Anderson Cancer Center and Moleculin Biotech, Inc.; and (iii) Patent and Technology License Agreement dated October 21, 2022*by and between The Board of The University Of Texas System on behalf of The University Of Texas M.D. Anderson Cancer Center and Moleculin Biotech, Inc.

On* November 4, 2024,the Compensation Committee of the Board of Directors took the following actions in connection with the executive compensation for the2023/2024* compensation year (* June 1, 2023to May 31, 2024)with its named executive officers (Walter Klemp, President and Chief Executive Officer; Jonathan P. Foster, Executive Vice President and Chief Financial Officer; and Dr. Donald Picker, Chief Scientific Officer): (i) cash bonuses in the aggregate amount of$735,000* were granted based on the full achievement of the goals and objectives for the compensation year, however the payment of the bonuses was accrued and will be paid the earlier of a)364 days or b) approval by the CEO after consultation with the Board of Directors; and (ii) the Compensation Committee agreed that the accrued bonuses will earn interest at a rate of8% per annum. In* April 2025,the Company paid50%* of the executive bonuses and accrued interest from the2023/2024 compensation year (* June 1, 2023to May 31, 2024).*

18